Moderna and the FDA: Vaccine Authorization, Approval, and Ongoing Review

Key Facts at a Glance

Moderna’s vaccines are regulated by the U.S. Food and Drug Administration (FDA) through well-defined pathways that balance rapid public health response with rigorous safety, effectiveness, and quality standards. Below is a concise reference for the most commonly asked questions about FDA oversight of Moderna’s products.

The FDA’s Role in Vaccine Regulation

The FDA is the U.S. agency responsible for protecting and promoting public health through the regulation of vaccines, drugs, and biological products. For vaccines, the FDA sets rigorous standards for manufacturing, labeling, and clinical evidence. Before a vaccine can be used in the United States, the sponsor—such as Moderna—must submit data that the agency’s scientific reviewers assess for safety, effectiveness, and quality. The FDA may authorize a vaccine for emergency use when clear benefits outweigh known risks under urgent public health circumstances, or approve it following a more comprehensive review when sufficient long-term data are available.

How Moderna Engages With the FDA

Moderna collaborates with the FDA across the entire product lifecycle, from initial development and clinical trials to ongoing monitoring after approval or authorization. This relationship includes pre-submission meetings, submission of study data, responsiveness to regulatory questions, and adherence to current good manufacturing practices. The FDA also inspects manufacturing sites and reviews each batch of vaccine before release when applicable. Because public health needs and scientific evidence evolve, the FDA may require updates to labels, dosing recommendations, or product composition, which Moderna must provide through supplements to its original authorization or application.

Authorizations and Approvals for COVID-19 Vaccines

During the public health emergency for COVID-19, the FDA issued Emergency Use Authorizations (EUAs) for multiple Moderna COVID-19 vaccine formulations. These authorizations allowed for the use of specific vaccines in defined populations when the potential benefits outweighed known and potential risks. Subsequently, Moderna pursued formal approval through the Biologics License Application (BLA) process, which involves a deeper review of manufacturing, clinical, and real-world data. The FDA approved the company’s COVID-19 vaccine, Spikevax, for active immunization to prevent COVID-19 in individuals 6 months and older, with ongoing updates to align with currently circulating variants and guidance from advisory committees.

From EUA to Full Approval

An EUA is a temporary authorization contingent on ongoing data submission and safety monitoring, whereas BLA approval reflects a more comprehensive evidentiary review. During the transition from EUA to approval, the FDA evaluated long-term follow-up data, manufacturing consistency, and effectiveness against emerging variants. Continued compliance with Good Manufacturing Practice (CGMP) is required for any approved product. The FDA also retains the authority to modify, suspend, or revoke authorizations or approvals if new evidence or public health circumstances change.

Staying Current With Variant-Based Updates

As SARS-CoV-2 variants emerge, the FDA, in consultation with advisory committees, may direct updates to vaccine strains. These updates are delivered through revised EUAs or supplement approvals that specify which variant strains are included, who should receive the updated vaccine, and dosing schedules. Moderna’s role is to produce and label these updated vaccines according to the latest regulatory requirements, ensuring that authorized formulations reflect the most current scientific understanding.

Other Vaccine Programs and FDA Interactions

Beyond COVID-19, Moderna has developed vaccines for other infectious diseases, and each program follows a distinct regulatory path. For seasonal influenza, mRNA-based flu vaccines have advanced through clinical trials and regulatory discussions. For respiratory syncytial virus (RSV), Moderna’s vaccine candidates have been evaluated under separate pathways, with approvals or authorizations varying by pathogen target and population. The FDA tailors review timelines and requirements based on the disease, target population, and available evidence, while maintaining consistent safety and effectiveness standards.

Program

• COVID-19: EUA and BLA for specific formulations; updated formulations authorized periodically based on variant guidance.
• Influenza: Investigational programs aligned with seasonal vaccine needs and regulatory requirements.
• RSV: Targeted programs for older adults and maternal immunization, subject to FDA review for each indication.

Safety Monitoring and Post-Authorization Obligations

After authorization or approval, the FDA continues to monitor vaccine safety through multiple systems. Health care providers are required to report certain adverse events to the Vaccine Adverse Event Reporting System (VAERS), and the FDA analyzes these reports for potential safety signals. Moderna is also obligated to conduct periodic safety updates, submit adverse event summaries, and implement risk management plans when necessary. The FDA may issue communications, update labels, or recommend changes to usage if new evidence of risks or benefits emerges.

Regulatory Timelines and Public Communication

While the FDA strives for predictable review timelines, the pace of vaccine development can vary depending on public health needs, data quality, and advisory committee recommendations. Information about authorizations, approvals, and updates is typically communicated through FDA press releases, advisory committee meetings, and product labeling. Moderna often provides parallel updates to investors and partners, but the FDA’s official communications remain the authoritative source for regulatory status. Always consult the current FDA product label and agency notices for the most accurate and actionable information.

Summary of Key Regulatory Milestones

The table below summarizes representative regulatory milestones and document types relevant to Moderna’s relationship with the FDA. Note that specifics may vary by product and indication.